Catalog No.: PC-22912Not For Human Use, Lab Use Only.
Bemnifosbuvir (AT-527, RG-6422) is a novel phosphoramidate prodrug of AT-511 that has potent in vitro activity against HCV (EC50=5-28 nM), also inhibits replication of SARS-CoV-2 with EC90 of 0.47 uM.
Bemnifosbuvir (AT-527, RG-6422) is a novel phosphoramidate prodrug of AT-511 that has potent in vitro activity against HCV (EC50=5-28 nM), also inhibits replication of SARS-CoV-2 with EC90 of 0.47 uM. AT-527 shows similar potency against human coronavirus (HCoV)-229E, HCoV-OC43, and SARS-CoV in Huh-7 cells, with little to no cytotoxicity was observed for AT-511 at concentrations up to 100 uM. Once in cells, AT-527 is converted into its triphosphate form, AT-9010, that presumably targets the viral RNA-dependent RNA polymerase (RdRp, nsp12), for incorporation into viral RNA. AT-9010 outcompetes all native nucleotides for NiRAN binding, inhibiting its nucleotidyltransferase activity.
